{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:38:38Z","timestamp":1754109518770},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,26]]},"DOI":"10.7759\/cureus.12290","type":"journal-article","created":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T08:12:02Z","timestamp":1608970322000},"source":"Crossref","is-referenced-by-count":5,"title":["Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale"],"prefix":"10.7759","author":[{"given":"Nosheen","family":"Nasir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faisal","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiren","family":"Habib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iffat","family":"Khanum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bushra","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1036","article-title":"Covid-19: WHO declares pandemic because of \"alarming levels\" of spread, severity, and inaction","volume":"368","author":"Mahase E","year":"2020","unstructured":"Mahase E. Covid-19: WHO declares pandemic because of \"alarming levels\" of spread, severity, and inaction. BMJ. 2020, 368:m1036. 10.1136\/bmj.m1036","journal-title":"BMJ"},{"key":"ref2","unstructured":"COVID-19 coronavirus pandemic. (2020). https.\/\/www.worldometers.info\/coronavirus\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore JB","year":"2020","unstructured":"Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020, 368:473-474. 10.1126\/science.abb8925","journal-title":"Science"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","volume":"71","author":"Qin C","year":"2020","unstructured":"Qin C, Zhou L, Hu Z, et al.. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020, 71:762-768. 10.1093\/cid\/ciaa248","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501120-20200224-00088","article-title":"Advances in the research of cytokine storm mechanism induced by corona virus disease 2019 and the corresponding immunotherapies [Article in Chinese]","volume":"36","author":"Chen C","year":"2020","unstructured":"Chen C, Zhang X, Ju Z, He W. Advances in the research of cytokine storm mechanism induced by corona virus disease 2019 and the corresponding immunotherapies [Article in Chinese]. Zhonghua Shao Shang Za Zhi. 2020, 36:005. 10.3760\/cma.j.cn501120-20200224-00088","journal-title":"Zhonghua Shao Shang Za Zhi"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli G","year":"2020","unstructured":"Cavalli G, De Luca G, Campochiaro C, et al.. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatology. 2020, 2:E325-E331. 10.1016\/S2665-9913(20)30127-2","journal-title":"Lancet Rheumatology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle D","year":"2020","unstructured":"McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020, 19:102537. 10.1016\/j.autrev.2020.102537","journal-title":"Autoimmun Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders JM","year":"2020","unstructured":"Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020, 323:1824-1836. 10.1001\/jama.2020.6019","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality","volume":"55","author":"Zhang C","year":"2020","unstructured":"Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020, 55:105954. 10.1016\/j.ijantimicag.2020.105954","journal-title":"Int J Antimicrob Agents"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8050695","article-title":"Tocilizumab for treatment of severe covid-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE)","volume":"8","author":"Colaneri M","year":"2020","unstructured":"Colaneri M, Bogliolo L, Valsecchi P, et al.. Tocilizumab for treatment of severe covid-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms. 2020, 8:695. 10.3390\/microorganisms8050695","journal-title":"Microorganisms"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30313-1","article-title":"COVACTA trial raises questions about tocilizumab's benefit in COVID-19","volume":"2","author":"Furlow B","year":"2020","unstructured":"Furlow B. COVACTA trial raises questions about tocilizumab's benefit in COVID-19. Lancet Rheumatology. 2020, 2:E592. 10.1016\/S2665-9913(20)30313-1","journal-title":"Lancet Rheumatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.23.20134072","article-title":"Treatment of ARDS and hyperinflammation in COVID-19 with IL-6 antagonist tocilizumab: a tertiary care experience from Pakistan [PREPRINT]","author":"Nasir N","year":"2020","unstructured":"Nasir N, Mahmood SF, Habib K, Khanum I, Jamil B. Treatment of ARDS and hyperinflammation in COVID-19 with IL-6 antagonist tocilizumab: a tertiary care experience from Pakistan [PREPRINT]. medRxiv. 2020, 10.1101\/2020.06.23.20134072","journal-title":"medRxiv"},{"key":"ref13","unstructured":"WHO. Interim guidance. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. (2020). Accessed: July 5, 2020: https:\/\/www.who.int\/docs\/default-source\/coronaviruse\/clinical-management-of-novel-cov.pdf."},{"key":"ref14","unstructured":"WHO. Clinical management of COVID- 19. interim guidance. (2020). Accessed: May 27, 2020: https:\/\/www.who.int\/publications\/i\/item\/clinical-management-of-covid-19."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30298-X","article-title":"COVID- 19: endgames","volume":"20","author":"The Lancet Infectious Diseases","year":"2020","unstructured":"The Lancet Infectious Diseases. COVID- 19: endgames. Lancet Infect Dis. 2020, 20:511. 10.1016\/S1473-3099(20)30298-X","journal-title":"Lancet Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID- 19: a single center experience","volume":"92","author":"Luo P","year":"2020","unstructured":"Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID- 19: a single center experience. J Med Virol. 2020, 92:814-818. 10.1002\/jmv.25801","journal-title":"J Med Virol"},{"key":"ref17","article-title":"Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19","volume":"38","author":"Sciascia S","year":"2020","unstructured":"Sciascia S, Apra F, Baffa A, et al.. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020, 38:529-532.","journal-title":"Clin Exp Rheumatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26308","article-title":"Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: a single-center cohort study","volume":"[Epub ahead of print]","author":"Fern\u00e1ndez-Ruiz M","year":"2020","unstructured":"Fern\u00e1ndez-Ruiz M, L\u00f3pez-Medrano F, P\u00e9rez-Jacoiste As\u00edn MA, et al.. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: a single-center cohort study. J Med Virol. 2020, [Epub ahead of print]:10.1002\/jmv.26308","journal-title":"J Med Virol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100418","article-title":"Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study","volume":"24","author":"Kewan T","year":"2020","unstructured":"Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study. EClinicalMedicine. 2020, 24:100418. 10.1016\/j.eclinm.2020.100418","journal-title":"EClinicalMedicine"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.07.036","article-title":"Appropriate use of tocilizumab in COVID-19 infection","volume":"99","author":"Keske \u015e","year":"2020","unstructured":"Keske \u015e, Tekin S, Sait B, et al.. Appropriate use of tocilizumab in COVID-19 infection. Int J Infect Dis. 2020, 99:338-343. 10.1016\/j.ijid.2020.07.036","journal-title":"Int J Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu X","year":"2020","unstructured":"Xu X, Han M, Li T, et al.. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020, 117:10970-10975. 10.1073\/pnas.2005615117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.12890\/2020_001675","article-title":"Tocilizumab in severe COVID-19 pneumonia and concomitant cytokine release syndrome","volume":"7","author":"van Kraaij TD","year":"2020","unstructured":"van Kraaij TD, Mostard RL, Ramiro S, et al.. Tocilizumab in severe COVID-19 pneumonia and concomitant cytokine release syndrome. Eur J Case Rep Intern Med. 2020, 7:001675. 10.12890\/2020_001675","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2020.05.001","article-title":"Tocilizumab therapy reduced intensive care unit admissions and\/or mortality in COVID-19 patients","volume":"50","author":"Klopfenstein T","year":"2020","unstructured":"Klopfenstein T, Zayet S, Lohse A, et al.. Tocilizumab therapy reduced intensive care unit admissions and\/or mortality in COVID-19 patients. Med Mal Infect. 2020, 50:397-400. 10.1016\/j.medmal.2020.05.001","journal-title":"Med Mal Infect"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/46169-tocilizumab-for-covid-19-acute-respiratory-distress-syndrome-outcomes-assessment-using-the-who-ordinal-scale","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:25:42Z","timestamp":1707506742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/46169-tocilizumab-for-covid-19-acute-respiratory-distress-syndrome-outcomes-assessment-using-the-who-ordinal-scale"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,26]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.12290","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,26]]}}}